JP7110199B2 - 抗第ＸＩ／ＸＩａ因子抗体による処置法 - Google Patents

抗第ＸＩ／ＸＩａ因子抗体による処置法 Download PDF

Info

Publication number
JP7110199B2
JP7110199B2 JP2019533396A JP2019533396A JP7110199B2 JP 7110199 B2 JP7110199 B2 JP 7110199B2 JP 2019533396 A JP2019533396 A JP 2019533396A JP 2019533396 A JP2019533396 A JP 2019533396A JP 7110199 B2 JP7110199 B2 JP 7110199B2
Authority
JP
Japan
Prior art keywords
antibody
fxi
seq
amino acid
fxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504110A (ja
JP2020504110A5 (https=
Inventor
フリードマン，カローラ
キーダー，ヤセル
レフコウィッツ，マーティン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020504110A publication Critical patent/JP2020504110A/ja
Publication of JP2020504110A5 publication Critical patent/JP2020504110A5/ja
Priority to JP2022115212A priority Critical patent/JP7500662B2/ja
Application granted granted Critical
Publication of JP7110199B2 publication Critical patent/JP7110199B2/ja
Priority to JP2024091065A priority patent/JP2024116221A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019533396A 2016-12-23 2017-12-22 抗第ＸＩ／ＸＩａ因子抗体による処置法 Active JP7110199B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022115212A JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2024091065A JP2024116221A (ja) 2016-12-23 2024-06-05 抗第ＸＩ／ＸＩａ因子抗体による処置法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US62/438,654 2016-12-23
US201762589851P 2017-11-22 2017-11-22
US62/589,851 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022115212A Division JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法

Publications (3)

Publication Number Publication Date
JP2020504110A JP2020504110A (ja) 2020-02-06
JP2020504110A5 JP2020504110A5 (https=) 2021-04-30
JP7110199B2 true JP7110199B2 (ja) 2022-08-01

Family

ID=61022382

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533396A Active JP7110199B2 (ja) 2016-12-23 2017-12-22 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2022115212A Active JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2024091065A Pending JP2024116221A (ja) 2016-12-23 2024-06-05 抗第ＸＩ／ＸＩａ因子抗体による処置法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022115212A Active JP7500662B2 (ja) 2016-12-23 2022-07-20 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2024091065A Pending JP2024116221A (ja) 2016-12-23 2024-06-05 抗第ＸＩ／ＸＩａ因子抗体による処置法

Country Status (9)

Country Link
US (3) US20200231701A1 (https=)
EP (1) EP3558370A2 (https=)
JP (3) JP7110199B2 (https=)
KR (3) KR102702288B1 (https=)
CN (2) CN110325211A (https=)
AU (2) AU2017383537B2 (https=)
CA (1) CA3048157A1 (https=)
IL (2) IL267519B2 (https=)
WO (1) WO2018116267A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru
JP7650807B2 (ja) * 2019-04-16 2025-03-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
BR112022012064A2 (pt) * 2019-12-20 2022-08-30 Anthos Therapeutics Inc Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法
CN120173947A (zh) * 2024-03-28 2025-06-20 施能康医药科技(苏州)有限公司 靶向凝血因子xi的核酸及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517305A (ja) 2012-05-10 2015-06-22 バイエル ファーマ アクチエンゲゼルシャフト 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
JP2018526976A (ja) 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
BR9913435A (pt) * 1998-08-28 2001-09-25 Genentech Inc Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
US8388959B2 (en) * 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
CN110325211A (zh) 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517305A (ja) 2012-05-10 2015-06-22 バイエル ファーマ アクチエンゲゼルシャフト 凝固因子ｘｉおよび／またはその活性化形態である因子ｘｉａに結合しうる抗体ならびにその用途
JP2018526976A (ja) 2015-06-26 2018-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法

Also Published As

Publication number Publication date
CA3048157A1 (en) 2018-06-28
IL267519A (en) 2019-08-29
WO2018116267A3 (en) 2018-08-02
IL316673A (en) 2024-12-01
KR20190099256A (ko) 2019-08-26
KR102702288B1 (ko) 2024-09-05
US20200231701A1 (en) 2020-07-23
KR102918597B1 (ko) 2026-01-28
JP7500662B2 (ja) 2024-06-17
AU2024287181A1 (en) 2025-03-06
IL267519B1 (en) 2024-12-01
CN110325211A (zh) 2019-10-11
JP2020504110A (ja) 2020-02-06
US20250197522A1 (en) 2025-06-19
AU2017383537B2 (en) 2024-10-03
EP3558370A2 (en) 2019-10-30
JP2022141831A (ja) 2022-09-29
KR20260023597A (ko) 2026-02-20
IL267519B2 (en) 2025-04-01
US20230002507A1 (en) 2023-01-05
AU2017383537A1 (en) 2019-06-27
JP2024116221A (ja) 2024-08-27
KR20240134248A (ko) 2024-09-06
WO2018116267A2 (en) 2018-06-28
CN118320078A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
JP7823009B2 (ja) 第ｘｉ因子抗体および使用方法
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP7139332B2 (ja) 第ｘｉ因子抗体および使用方法
BR112017027778B1 (pt) Anticorpo anti-fxi e/ou anti-fxia ativado isolado, usos do mesmo, composição farmacêutica, medicamento, sequência de ácido nucleico, e vetor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250